MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
8.72
-0.41
-4.49%
After Hours: 8.72 0 0.00% 16:40 11/20 EST
OPEN
9.07
PREV CLOSE
9.13
HIGH
9.27
LOW
8.69
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
8.41
MARKET CAP
785.05M
P/E (TTM)
-3.6773
1D
5D
1M
3M
1Y
5Y
1D
Syndax Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 5h ago
Syndax Pharmaceuticals Price Target Cut to $31.00/Share From $33.00 by UBS
Dow Jones · 5h ago
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $31
Benzinga · 5h ago
Syndax price target lowered to $31 from $33 at UBS
TipRanks · 10h ago
UBS Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
TipRanks · 10h ago
Weekly Report: what happened at SNDX last week (1109-1113)?
Weekly Report · 4d ago
Kura Oncology: Less Than Nothing By The First Readout
Seeking Alpha · 4d ago
Syndax Earnings Call Highlights Strong Growth and Pipeline Momentum
TipRanks · 5d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.